key: cord-0987231-ci5z4733
authors: Hilty, Matthias Peter; Keiser, Stefanie; Wendel Garcia, Pedro D.; Moser, André; Schuepbach, Reto A.
title: mRNA-based SARS-CoV-2 vaccination is associated with reduced ICU admission rate and disease severity in critically ill COVID-19 patients treated in Switzerland
date: 2022-01-20
journal: Intensive Care Med
DOI: 10.1007/s00134-021-06610-z
sha: e4289c39429dd94321e54dd83626a9df869a084a
doc_id: 987231
cord_uid: ci5z4733

nan

Large-scale vaccination programs were incepted in response to the coronavirus disease 2019 pandemic. Although high effectiveness was initially indicated [1] , public-health factors and emerging virus variants have contributed to changes in characteristics of critically ill COVID-19 patients [2] . To monitor the effects of the vaccination program on the development of critical illness due to COVID-19, we compared the characteristics and outcome of vaccinated versus non-vaccinated patients admitted to the intensive care unit (ICU) via the prospective observational Risk Stratification in COVID-19 patients in the ICU (RISC-19-ICU) registry [3] . Mixed-model analysis accounted for potential treatment center effects, and analysis was adjusted for age, sex and immunosuppression. To minimize variation in viral epidemiology, vaccination programs and ICU resources, we focused only on patients admitted to ICUs in Switzerland (Appendix S1).

Of 4351 critically ill COVID-19 patients enrolled internationally by September 30th, 2021, 2253 were treated in Switzerland. Within this cohort, 964 patients admitted to the ICU during the vaccination program were included Comparative statistics between vaccinated and nonvaccinated patients are detailed in Fig. 1 and Table S1 . Vaccinated patients were 6.8 (CI 2.0-11.6) years older (p < 0.01) and had more comorbidities [RR (CI) 1.5 (1.1-2.1), p = 0.03], especially immunosuppression [OR (CI) 5.8 (2.7-13) , p < 0.0001]. They presented at ICU admission with lower respiratory Sequential Organ Failure Assessment (SOFA) sub-score, need for mechanical ventilation, and 3 point lower overall SOFA score, alongside lower cardiovascular, coagulatory, renal and central nervous system sub-scores. ICU length-of-stay was reduced by 6 (CI − 11.7 to − 0.5) days in survivors (p = 0.03), with similar ICU mortality at 23.3 versus 22.4% [HR (CI) 1.4 (0.6-3), p = 0.41]. Effects were preserved or strengthened by adjustment.

Near real-time registry data thus confirm previous implications of reduced COVID-19 hospitalization rates with increasing vaccination-ratio [4] , and suggest an even larger effect regarding the development of critical illness by showing that less than 4% of COVID-19 patients admitted to ICU in the first 9 months of the vaccination program in Switzerland were vaccinated. Two main findings indicate a positive effect of the vaccination program. First, despite older age and elevated risk profile, vaccinated ICU patients had less severe lung and systemic organ failure, need for mechanical ventilation and shorter ICU length-of-stay, yet still similar ICU mortality. A trend towards higher D-dimer and lower ferritin levels could indicate differences in coagulatory activation and immune dysregulation, warranting further investigation. Second, a reduced disease severity was observed as compared to non-vaccinated patients despite an increasing prevalence of virus variants (Fig. S2 C) and reports of breakthrough infections in vaccinated individuals [5] . Nevertheless, the higher prevalence of comorbidities in vaccinated patients, together with previously described, attenuated in vitro vaccine response in immunocompromised patients, emphasize the importance of ongoing improvements to vaccination regimes, e.g., by adding booster doses.

In conclusion, our data strongly support a protective effect of the mRNA-based COVID-19 vaccines in preventing critical illness and unfavorable disease course even in patients with known risk factors for COVID-19 and indicate an important role in relieving ICU resources.

The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s00134-021-06610-z. (See figure on previous page.) Fig. 1 Effect of vaccination status on the patient characteristics and initial treatment at ICU admission (A), and on the outcome of critically ill COVID-19 patients (B), showing for vaccinated patients admitted to the ICU, less severe lung and systemic organ failure, need for mechanical ventilation and shorter ICU length of stay, yet still similar ICU mortality despite older age and elevated risk profile. The age distribution of patients admitted to the ICU shows a marked right-shift, with only 12% of the vaccinated critically ill patients below the age of 60 years (C). Blue dots and lines represent the estimate and 95% CI of mixed model analysis with vaccination status entered as fixed effect and treatment center as random effect, whereas red dots and lines represent the estimate and 95% CI of adjusted mixed model analysis with age, sex and presence of immunosuppression-related disease as pre-existing condition as additional fixed effects. All included patients are represented in panel (A, n = 964), whereas panel (B) encompasses patients discharged from the ICU by September 30th, 2021 for the crude analysis graph (n = 915), and ICU survivors for the adjusted analysis graph (n = 710). ICU mortality estimates were modeled using a Cox proportional hazards model, with an underlying time scale of ICU admission until date of death or date of discharge which was defined as censoring event, with ICU mortality entered as event and ICU survival entered as censored event. Estimates are given as the mean difference (CI) for continuous variables, RR (CI) for counts, OR (CI) for binary categorical variables, and HR (CI) for survival analysis, the secondary scale applies to the reporting of RR, OR and HR as denoted (*). The vertical grey line represents the line of no effect. Estimates to the right of the grey line are associated with the vaccination, and to the left, with the lack of vaccination scilicet inversely with the vaccination. Complete results for crude and adjusted analyses in the overall and subpopulations are listed in Supplementary  Table S1 and Supplementary Table S2 . RR, rate ratio; OR, odds ratio; HR, hazard ratio; CI, 95% confidence interval

Switzerland: RISC-19-ICU Board (Matthias P. Hilty, MD; Reto A

D.); Institute of Intensive Care Medicine

Groupement Hospitalier de l'Ouest Lémanique-Hopital de Nyon

Department for Intensive Care Medicine

Department of Anesthesiology and Intensive Care Medicine, Cantonal Hospital St

Frauenfeld (Alexander Dullenkopf, MD; Lina Petersen, MD); Division of Neonatal and Pediatric Intensive Care

Pediatric Intensive Care Unit, University Hospital Lausanne

Paediatric Intensive Care Unit, Children's Hospital of Eastern Switzerland

Spitalzentrum Oberwallis

Nuria Zellweger); Department of Intensive Care Medicine

Service d' Anesthesiologie, EHNV

Effectiveness of mRNA Covid-19 Vaccine among US Health Care Personnel

RISC-19-ICU Investigators For Switzerland (2021) Near real-time observation reveals increased prevalence of young patients in the ICU during the emerging third SARS-CoV-2 wave in Switzerland

RISC-19-ICU Investigators (2020) Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: initial report of the international RISC-19-ICU prospective observational cohort

Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings

COVID-19 breakthrough infections in vaccinated health care workers

This work is endorsed by the Swiss Society of Intensive Care Medicine. We want to thank all nurses, physicians and other healthcare workers in our collaborating centers for their tireless and brave efforts in the care of their patients, without you this health care emergency could not be overcome. We thank Stephan M. Jakob, Yok-Ai Que, Anne-Aylin Sigg, Thierry Fumeaux, Philippe Guerci, Jonathan Montomoli, and Tanja Stadler for their invaluable help with this manuscript. The members of RISC-19-ICU Investigators for

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Accepted: 21 December 2021